Hormonal
Retatrutide, a triple hormone agonist (GLP-1, GIP, glucagon), administered subcutaneously once weekly, produces substantial, progressive weight loss (up to 24.2%) and HbA1c reduction in adults with obesity and type 2 diabetes, significantly outperforming placebo and, in some metrics, the dual agonist tirzepatide.
Retatrutide is a once-weekly injection that combines three hormones to help you lose significant weight and lower blood sugar. It works best if you start with a low dose and increase it slowly to manage stomach side effects. While it causes more nausea than other drugs, it leads to greater weight loss, potentially helping you reach a level of weight loss that can put type 2 diabetes into remission. You should expect regular check-ins and lifestyle counseling alongside the medication.
In summary, retatrutide is highly effective drug in causing substantial weight loss and HbA1c reduction. ... At 48 weeks, the decrease was 8.7% to 24.2% versus 2.1% with placebo. ... retatrutide may be superior to tirzepatide in both parameters, particularly weight loss
Why this rating
Based on Phase 2 randomized controlled trials (n=338 obesity, n=281 diabetes), which are robust but not yet Phase 3 large-scale outcomes data.
Source
Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes
Nasser Mikhail · Current Research in Diabetes & Obesity Journal · 2023
DOI 10.19080/crdoj.2023.16.555949
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →